Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00888316 · ClinicalTrials.gov registry record

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

A clinical trial of Cancer and Hematopoietic Stem Cell Transplantation, sponsored by Masonic Cancer Center, University of Minnesota.

Completed
Registry status
112
Enrollment target
1
Study location

NCT00888316: Completed study of Cancer and Hematopoietic Stem Cell Transplantation, sponsored by Masonic Cancer Center, University of Minnesota.

NCT00888316 is a study of Cancer and Hematopoietic Stem Cell Transplantation that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 112 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00888316, a study of Cancer and Hematopoietic Stem Cell Transplantation, has completed, sponsored by Masonic Cancer Center, University of Minnesota.

COMPLETED
Registry status
112 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Learning about the effect of excess iron in the liver of patients undergoing donor stem cell transplant may help doctors plan treatment. PURPOSE: This study is investigating the effects of iron overload in patients undergoing donor stem cell transplant.

Primary Outcome

Number of patients alive at 1 year.

Interventions

  • PROCEDURE magnetic resonance imaging
  • PROCEDURE Serum ferritin

Study Locations (1)

Minnesota

  • University of Minnesota Children's Hospital - Fairview - Minneapolis

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2008-12
Est. Completion 2012-06

What the finished NCT00888316 record still lists

NCT00888316 is an observational study that tracks outcomes without assigning an intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which magnetic resonance imaging is the first listed.

NCT00888316 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00888316 about?

NCT00888316 is a clinical study titled "Iron Overload in Patients Undergoing Donor Stem Cell Transplant". RATIONALE: Learning about the effect of excess iron in the liver of patients undergoing donor stem cell transplant may help doctors plan treatment. PURPOSE: This study is investigating the effects of iron overload in patients undergoing donor stem cell transplant.

What is the current status of trial NCT00888316?

This trial is currently completed. The enrollment target is 112 participants. The study started on 2008-12. Estimated completion is 2012-06.

What conditions does trial NCT00888316 study?

This clinical trial studies the following conditions: Cancer, Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation.

What interventions are being tested in trial NCT00888316?

The interventions under investigation include: magnetic resonance imaging (PROCEDURE), Serum ferritin (PROCEDURE).

Who is sponsoring clinical trial NCT00888316?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00888316 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00888316's enrollment target sits among peer trials

112 300th of 615 higher than 314 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00888316, the US trial registry maintained by the National Library of Medicine. NCT00888316 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.